Physician profile
Keith E Matthews
NPI 1063814952
$19,719.35
in general payments reported to CMS, 2019-2025
6 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,026 · 2022: $931 · 2023: $1,254 · 2024: $3,742 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,900 · Travel and Lodging: $5,462 · Food and Beverage: $3,901 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,900.00 |
| Travel and Lodging | $5,461.70 |
| Food and Beverage | $3,901.07 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $15,943.59 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $2,451.00 | 2021-2025 | Biktarvy |
| Janssen Biotech, INC. | $578.83 | 2021-2023 | Symtuza |
| Theratechnologies INC. | $451.63 | 2021-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $276.87 | 2021-2025 | Pifeltro, Capvaxive, Steglujan |
| Abbvie INC. | $17.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.